Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 16/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486119 | 1.00 | HCAR2 (0.46) | HCAR2IDO1MEN1ALDH1A1KMT2A | |
| SCHEMBL13631651 | 1.00 | HCAR2 (0.46) | HCAR2IDO1MEN1ALDH1A1KMT2A | |
| SCHEMBL13638161 | 1.00 | HCAR2 (0.46) | HCAR2IDO1MEN1ALDH1A1KMT2A | |
| SCHEMBL4489387 | 0.81 | HCAR2 (0.40) | HCAR2IDO1MEN1ALDH1A1KMT2A | |
| SCHEMBL13631466 | 0.81 | HCAR2 (0.40) | HCAR2IDO1MEN1ALDH1A1KMT2A | |
| SCHEMBL13631525 | 0.81 | HCAR2 (0.40) | HCAR2IDO1MEN1ALDH1A1KMT2A | |
| SCHEMBL4524411 | 0.79 | HCAR2 (0.44) | HCAR2ALDH1A1KMT2AGP6HPGDS | |
| SCHEMBL4489094 | 0.79 | HCAR2 (0.44) | HCAR2ALDH1A1KMT2AGP6HPGDS | |
| SCHEMBL4481142 | 0.77 | HCAR2 (0.58) | HCAR2 | |
| SCHEMBL13631570 | 0.77 | HCAR2 (0.58) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612106-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060205955-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ACE, ACE2, AGTR2 | HCAR2 300/4885IDO1 1667/4885MEN1 4780/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | HCAR2 300/4885IDO1 1667/4885MEN1 4780/4885 |
| US-20060205955-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | HCAR2 300/4885IDO1 1667/4885MEN1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.